Disseminated Intravascular Coagulation D004211

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Coagulation Disorders » Disseminated Intravascular Coagulation

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Thrombophilia » Disseminated Intravascular Coagulation

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Hemorrhagic Disorders » Disseminated Intravascular Coagulation

Description

A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.   MeSH

Phase 4 Indicated Drugs (1)

Phase 3 Indicated Drugs (2)

Other Experimental Indicated Drugs (1)


Organization Involved with Phase 4 Indications (1)

Organization Involved with Phase 2 Indications (3)

Organization Involved with Other Experimental Indications (2)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.